Tañeza, Baby Girl .

HRN: 28-92-61  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/04/2026
AMPICILLIN 250MG (VIAL)
05/04/2026
05/10/2026
IVT
115mg
Q12H
NAMF (PROM X 24 Hours)
Pending Pharmacy Acceptance 

 Indication:  ProphylaxisEmpiric    Type of Infection:  Bloodstream    Compliance to guidelines: